University of Glasgow

Kiran Mazumdar-Shaw, founder of Biocon, is India’s richest self-made woman with a net worth of Rs 28,835 crore. She donated Rs 63 crore to the University of Glasgow and focuses on affordable cancer care through her philanthropic initiatives. Recognized globally, she ranks 82nd on Forbes World’s 100 Most Powerful Women list.

Optogenetic tools for gene expression control in Synechococcus sp. PCC 7002 were studied, focusing on YF1/FixJ and CcaS/CcaR systems. CcaS/CcaR, from Synechocystis sp. PCC 6803, showed effective light-responsive performance, while YF1/FixJ had limited success. Genetic modifications enhanced CcaS/CcaR activity, highlighting challenges in transferring optogenetic tools across species.

GCAR and AstraZeneca will evaluate AZD1390 in GBM AGILE trial for newly diagnosed glioblastoma, with recruitment starting Q2 2025. GBM AGILE, the first global adaptive platform trial for glioblastoma, aims to identify effective therapies through adaptive randomization. AZD1390, an ATM kinase inhibitor, showed preliminary efficacy and manageable safety profile in Phase I data.

GCAR to evaluate AstraZeneca's AZD1390 in GBM AGILE trial for glioblastoma, aiming to expedite effective therapy identification. Recruitment for newly diagnosed patients starts Q2 next year. Data may support BLA and NDA submissions to the FDA.

AstraZeneca’s AZD1390 joins GBM AGILE, a Phase 2/3 adaptive platform trial for glioblastoma, targeting newly diagnosed patients; recruitment starts Q2 2025. GBM AGILE aims to rapidly identify effective therapies through adaptive randomization and a seamless phase 2/3 design, potentially enabling new drug applications. AZD1390, an ATM kinase inhibitor, shows promise in preclinical and Phase I trials as a radiosensitizer.

A study reveals salmonella can be genetically engineered to combat bowel cancer, with T cells in mice responding to engineered forms. The research identifies a protein hindering T cell function, offering a genetic target to enhance therapy. Further research is needed to refine this bacterial treatment.

GCAR to evaluate AstraZeneca's AZD1390, an ATM kinase inhibitor, in GBM AGILE trial for newly diagnosed glioblastoma, with recruitment starting in early 2025. AZD1390, a brain-penetrant compound, has shown activity in combination with radiation and a manageable safety profile in a phase I trial.